La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Dextech Medical Gestion

Gestion contrôle des critères 1/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Anders Holmberg

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	20.6yrs
Propriété du PDG	8.5%
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	10.4yrs

Mises à jour récentes de la gestion

Recent updates

What Kind Of Shareholders Hold The Majority In Dextech Medical AB's (NGM:DEX) Shares?

Feb 17

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

Dec 12

PDG

Anders Holmberg (73 yo)

20.6yrs

Titularisation

SEK 596,112

Compensation

Mr. Anders Ragnarsson Holmberg, M.D. is the Founder of Dextech Medical AB (publ) and serves as its Chief Executive Officer and Managing Director and served as its President. Mr. Holmberg has been a Directo...

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Anders Holmberg	Founder	20yrs	SEK 596.11k	8.51% SEK 7.2m
Peter Benson	Director	1.6yrs	pas de données	pas de données
Meir Wilchek	Member of Scientific Advisory Board	no data	pas de données	pas de données
Rolf Eriksson	Director	10.4yrs	pas de données	pas de données
Svante Wadman	Director	no data	pas de données	21.47% SEK 18.3m
Per Asplund	Director	11.4yrs	pas de données	pas de données
Lennart Meurling	Member of Scientific Advisory Board	no data	pas de données	1.56% SEK 1.3m
Marcela Marquez	Member of Scientific Advisory Board	no data	pas de données	pas de données
Ulf Lerner	Member of Scientific Advisory Board	no data	pas de données	pas de données
Andreas Segerros	Chairman of the Board	2.3yrs	pas de données	pas de données

10.4yrs

Durée moyenne de l'emploi

71yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration DEX sont chevronnés et expérimentés (durée moyenne d'administration 10.4 ans).

Dextech Medical Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Dextech Medical AB, Annual General Meeting, Oct 31, 2023

No independent directors

Dextech Medical AB Appoints Andreas Segerros as A New Ordinary Board Member

No independent directors

Recent updates

Dextech Medical AB Announces Continued Positive Results from Myeloma Study

Third quarter 2024 earnings released: kr0.077 loss per share (vs kr0.079 loss in 3Q 2023)

DexTech Medical Announces New Positive Results from the Myeloma Study

New major risk - Market cap size

Second quarter 2024 earnings released: kr0.058 loss per share (vs kr0.065 loss in 2Q 2023)

New major risk - Share price stability

Dextech Medical AB Announces Positive Results from the Myeloma Study

DexTech Medical Informs About the Myeloma Study, the First Patient Is Treated

First quarter 2024 earnings released: kr0.05 loss per share (vs kr0.044 loss in 1Q 2023)

Dextech Medical AB, Annual General Meeting, Oct 31, 2023

Full year 2023 earnings released: kr0.25 loss per share (vs kr0.31 loss in FY 2022)

New minor risk - Share price stability

Third quarter 2023 earnings released: kr0.079 loss per share (vs kr0.061 loss in 3Q 2022)

Second quarter 2023 earnings released: kr0.065 loss per share (vs kr0.076 loss in 2Q 2022)

Dextech Medical AB to Report Fiscal Year 2024 Results on Aug 30, 2024

No independent directors

First quarter 2023 earnings released: kr0.044 loss per share (vs kr0.063 loss in 1Q 2022)

Dextech Medical AB Announces Upcoming Multiple Myeloma Study

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.41 loss in FY 2021)

Dextech Medical AB to Report Q1, 2023 Results on Oct 27, 2022

Dextech Medical AB Announces Application Approval for Myeloma Study from Medical Products Agency

Dextech Medical AB Appoints Andreas Segerros as A New Ordinary Board Member

Third quarter 2022 earnings released: kr0.061 loss per share (vs kr0.10 loss in 3Q 2021)

No independent directors

DexTech Medical to Soon Advance into the Clinical Phase in Multiple Myeloma with the Main Candidate OsteoDex

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Dextech Medical (NGM:DEX) Is In A Good Position To Deliver On Growth Plans

Full year 2021 earnings released: kr0.41 loss per share (vs kr0.52 loss in FY 2020)

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

Full year 2021 earnings released: kr0.41 loss per share (vs kr0.52 loss in FY 2020)

DexTech Medical AB Plans New Clinical Study on Multiple Myeloma

We're Not Very Worried About Dextech Medical's (NGM:DEX) Cash Burn Rate

DexTech Medical AB Confirms Very Positive Results from Myeloma Studies

Third quarter 2021 earnings released: kr0.10 loss per share (vs kr0.13 loss in 3Q 2020)

What Kind Of Shareholders Hold The Majority In Dextech Medical AB's (NGM:DEX) Shares?

New 90-day high: kr59.40

Second quarter 2021 earnings released: kr0.10 loss per share (vs kr0.13 loss in 2Q 2020)

DexTech Medical AB Receives Positive Results Regarding Multiple Myeloma

New 90-day low: kr45.20

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

First quarter earnings released

Full year earnings released - kr0.52 loss per share

Full year earnings released - kr0.52 loss per share

New 90-day low - kr38.00

New 90-day low - kr42.00

New 90-day low - kr45.00

PDG

Titularisation

Compensation

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen